Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC
Abstract
Mucormycosis is a severe infection that requires prompt antifungal therapy. Although liposomal amphotericin B (L-AMB) is the standard treatment, its toxicity may limit its use. We report the case of a patient with diabetes mellitus and rhinocerebral mucormycosis who developed brain abscesses despite L-AMB and surgical interventions. After switching to isavuconazole (ISCZ) and continuing surgical management and optimization of underlying conditions, clinical and radiological improvements were observed. Although partial maxillary bone loss occurred during follow-up, the ISCZ was continued for more than one year without adverse events, and the patient remained clinically stable. Notably, although the isolate showed an ISCZ MIC >8 μg/mL, a clinical improvement was observed with multidisciplinary management.
Related
- High-flow nasal cannula versus standard oxygen therapy for adult acute hypoxemic respiratory failure: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment
- Rhino-orbito-cerebral mucormycosis (ROCM) in eastern Iran: a six-year dual-center retrospective observational study of 329 patients.
- Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as initial respiratory support during minimally invasive surfactant therapy in preterm infants with respiratory distress syndrome: a retrospective real-world cohort study
- Implementation of i‑PARIHS-guided pulmonary rehabilitation in patients receiving oxygen by high‑flow nasal cannula
- High-Flow Nasal Cannula in Adult Acute Care: Physiological Mechanisms, Clinical Evidence, and Persistent Misconceptions
BibTeX
@article{mori2026isavuconazole,
title = {{Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC}},
author = {Takeo Mori and Kazuhisa Kamiyama and Sakura Koyama and Dai Nakase and Yusuke Nakamura and Takahiro Sato and Taito Miyazaki and Tadashi Maeda and Misaki Nakamura and Masakazu Sasaki and Akira Watanabe and Sadako Yoshizawa and Kazuhiro Tateda and Yosuke Sasaki},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7672-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7672-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Isavuconazole Therapy for Nasal-Cerebral Mucormycosis with High Isavuconazole MIC
AU - Takeo Mori
AU - Kazuhisa Kamiyama
AU - Sakura Koyama
AU - Dai Nakase
AU - Yusuke Nakamura
AU - Takahiro Sato
AU - Taito Miyazaki
AU - Tadashi Maeda
AU - Misaki Nakamura
AU - Masakazu Sasaki
AU - Akira Watanabe
AU - Sadako Yoshizawa
AU - Kazuhiro Tateda
AU - Yosuke Sasaki
PY - 2026
DA - 2026/07/18
JO - Internal Medicine
DO - 10.2169/internalmedicine.7672-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7672-26/_article
AB - Mucormycosis is a severe infection that requires prompt antifungal therapy. Although liposomal amphotericin B (L-AMB) is the standard treatment, its toxicity may limit its use. We report the case of a patient with diabetes mellitus and rhinocerebral mucormycosis who developed brain abscesses despite L-AMB and surgical interventions. After switching to isavuconazole (ISCZ) and continuing surgical management and optimization of underlying conditions, clinical and radiological improvements were observed. Although partial maxillary bone loss occurred during follow-up, the ISCZ was continued for more than one year without adverse events, and the patient remained clinically stable. Notably, although the isolate showed an ISCZ MIC >8 μg/mL, a clinical improvement was observed with multidisciplinary management.
SN - 1349-7235
SN - 0918-2918
ER -